{"id":"placebo-repaglinide","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1272","moleculeType":"Small molecule","molecularWeight":"452.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Repaglinide binds to sulfonylurea receptors on pancreatic beta cells, leading to closure of ATP-sensitive potassium channels and subsequent depolarization. This triggers calcium influx and insulin exocytosis, thereby lowering blood glucose levels. The drug has a rapid onset and short duration of action, making it suitable for mealtime glucose control.","oneSentence":"Repaglinide is a meglitinide that stimulates insulin secretion from pancreatic beta cells by closing ATP-sensitive potassium channels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:01:20.322Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06566794","phase":"NA","title":"KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2024-08-22","conditions":"Drug Interaction","enrollment":12},{"nctId":"NCT05998837","phase":"PHASE2, PHASE3","title":"GLUcose Transport and REnalPROtection in Chronic Kidney Disease","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","startDate":"2021-04-13","conditions":"Chronic Kidney Disease, Diabetes Mellitus, Type 2, Hypertension","enrollment":34},{"nctId":"NCT06196580","phase":"PHASE1","title":"PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-01-04","conditions":"Gout and Hyperuricemia","enrollment":24},{"nctId":"NCT05555823","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib","status":"COMPLETED","sponsor":"Atriva Therapeutics GmbH","startDate":"2022-06-23","conditions":"Healthy","enrollment":96},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":585},{"nctId":"NCT00763412","phase":"NA","title":"Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis","status":"COMPLETED","sponsor":"Arbelaez, Ana Maria","startDate":"2006-11","conditions":"Cystic Fibrosis Related Diabetes, Pancreatic Insufficiency","enrollment":31},{"nctId":"NCT01798706","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Type 2 Diabetes","enrollment":350},{"nctId":"NCT01698931","phase":"PHASE4","title":"Efficacy of Repaglinide in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-04-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":9},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00072904","phase":"PHASE3","title":"Diabetes Therapy to Improve BMI and Lung Function in CF","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2001-06","conditions":"Cystic Fibrosis, Diabetes Mellitus","enrollment":108},{"nctId":"NCT00118963","phase":"PHASE4","title":"Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2003-01","conditions":"Diabetes Mellitus, Type 2","enrollment":102},{"nctId":"NCT00118950","phase":"PHASE4","title":"Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2001-03","conditions":"Diabetes Mellitus, Type 2","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo-Repaglinide","genericName":"Placebo-Repaglinide","companyName":"Steno Diabetes Center Copenhagen","companyId":"steno-diabetes-center-copenhagen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Repaglinide is a small molecule that blocks the sulfonylurea receptor 1, Kir6.2, and is used to treat Type 2 Diabetes Mellitus. It is classified as a blocker in the drug class.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}